# Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

> **NCT02907710** · PHASE3 · UNKNOWN · sponsor: **First Affiliated Hospital of Guangxi Medical University** · enrollment: 300 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **DRUG:** Endostar
- **DRUG:** DDP

## Key facts

- **NCT ID:** NCT02907710
- **Lead sponsor:** First Affiliated Hospital of Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2018-11
- **Final completion:** 2019-11
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2016-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02907710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02907710, "Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02907710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*